<p>随着美国股市面临挑战，主要指数出现周度亏损，国债收益率达到四个月来的最高点，投资者正在密切关注各个行业的潜在机会。便士股票通常与较小或较新的公司相关，对于那些寻求主流市场巨头之外的增长前景的投资者来说，仍然是一个引人注目的领域。尽管今天被认为有些小众，但便士股票在财务健康和行业内战略定位良好的情况下，仍然可以提供显著的潜力。</p>
<h3>美国十大便士股票</h3>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>名称</strong></td>
<td><strong>股价</strong></td>
<td><strong>市值</strong></td>
<td><strong>收益与风险</strong></td>
</tr>
<tr>
<td>Dingdong (Cayman) (DDL)</td>
<td>$2.61</td>
<td>$559.34M</td>
<td>✅ 4 ⚠️ 1 查看分析 </td>
</tr>
<tr>
<td>Waterdrop (WDH)</td>
<td>$1.79</td>
<td>$647.38M</td>
<td>✅ 4 ⚠️ 0 查看分析 </td>
</tr>
<tr>
<td>WM Technology (MAPS)</td>
<td>$0.825</td>
<td>$141.09M</td>
<td>✅ 4 ⚠️ 1 查看分析 </td>
</tr>
<tr>
<td>LexinFintech Holdings (LX)</td>
<td>$3.00</td>
<td>$504.79M</td>
<td>✅ 4 ⚠️ 2 查看分析 </td>
</tr>
<tr>
<td>Tuya (TUYA)</td>
<td>$2.25</td>
<td>$1.36B</td>
<td>✅ 4 ⚠️ 1 查看分析 </td>
</tr>
<tr>
<td>CI&amp;T (CINT)</td>
<td>$4.73</td>
<td>$614.03M</td>
<td>✅ 5 ⚠️ 0 查看分析 </td>
</tr>
<tr>
<td>Golden Growers Cooperative (GGRO.U)</td>
<td>$5.00</td>
<td>$77.45M</td>
<td>✅ 1 ⚠️ 5 查看分析 </td>
</tr>
<tr>
<td>Cricut (CRCT)</td>
<td>$4.31</td>
<td>$912.62M</td>
<td>✅ 2 ⚠️ 2 查看分析 </td>
</tr>
<tr>
<td>BAB (BABB)</td>
<td>$0.91</td>
<td>$6.61M</td>
<td>✅ 2 ⚠️ 3 查看分析 </td>
</tr>
<tr>
<td>Lifetime Brands (LCUT)</td>
<td>$3.90</td>
<td>$88.36M</td>
<td>✅ 3 ⚠️ 2 查看分析 </td>
</tr>
</tbody>
</table>
<p>点击这里查看我们美国便士股票筛选器的 334 只股票完整列表。</p>
<p>让我们回顾一些我们筛选出的显著股票。</p>
<h2>ATA Creativity Global (AACG)</h2>
<p><strong>Simply Wall St 财务健康评级：</strong> ★★★★☆☆</p>
<p><strong>概述：</strong> ATA Creativity Global 及其子公司在中国和国际上提供教育服务，市值为 3684 万美元。</p>
<p><strong>运营：</strong> 公司的收入部分包括来自细分调整的人民币 2.5691 亿元和其他教育服务的人民币 2299 万元。</p>
<p><strong>市值：</strong> $36.84M</p>
<p>ATA Creativity Global 市值为 3684 万美元，尽管尚未盈利，但其财务状况有所改善。公司在过去一年中显著减少了净亏损，并在 2025 年第三季度报告了人民币 237 万元的净收入，而之前则是净亏损。其短期资产超过长期负债，但不足以覆盖短期负债，突显出潜在的流动性问题。最近通过股权发行筹集 885 万美元的努力表明其持续的资本需求。尽管管理层和董事会经验丰富，但该股票仍然高度波动，周度波动率从 18% 降至 12%。</p>
<ul>
<li>点击这里访问我们的完整财务健康分析报告，以了解 ATA Creativity Global 的动态。</li>
<li>通过查看我们的业绩历史报告，了解 ATA Creativity Global 的表现记录。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/72e41983-3668-429b-8c7c-04ae55a7571c/chart/debt-equity-history-analysis?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/72e41983-3668-429b-8c7c-04ae55a7571c/chart/debt-equity-history-analysis"/></p>
<p>AACG 债务与股本历史及分析截至 2026 年 1 月</p>
<h2>Aldeyra Therapeutics (ALDX)</h2>
<p><strong>Simply Wall St 财务健康评级：</strong> ★★★★★☆</p>
<p><strong>概述：</strong> Aldeyra Therapeutics, Inc.是一家生物技术公司，专注于发现和开发针对免疫介导和代谢疾病的疗法，市值约为 2.7855 亿美元。</p>
<p><strong>运营：</strong> Aldeyra Therapeutics, Inc.尚未报告任何收入部分。</p>
<p><strong>市值：</strong> $278.55M</p>
<p>Aldeyra Therapeutics 市值为 2.7855 亿美元，尚未产生收入且仍处于亏损状态，但在过去五年中已成功减少亏损。公司最近因额外数据请求而面临 FDA 对其 reproxalap NDA 的延期，但未收到该机构的重大缺陷。Aldeyra 的现金状况超过其总债务，为其运营提供了一年以上的充足资金。尽管股价波动性高且股本回报率为负，Aldeyra 经验丰富的管理层和董事会为其在免疫介导疗法的进展提供了稳定性。</p>
<ul>
<li>通过阅读我们的资产负债表健康报告，深入了解 Aldeyra Therapeutics 的表现。</li>
<li>在这里了解 Aldeyra Therapeutics 的未来增长轨迹。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/55e4738e-9ff5-4d4f-8334-fd9b51fc6541/chart/debt-equity-history-analysis?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/55e4738e-9ff5-4d4f-8334-fd9b51fc6541/chart/debt-equity-history-analysis"/></p>
<p>ALDX 债务与股本历史及分析截至 2026 年 1 月</p>
<h2>MediciNova (MNOV)</h2>
<p><strong>Simply Wall St 财务健康评级：</strong> ★★★★★★</p>
<p><strong>概述：</strong> MediciNova, Inc.是一家生物制药公司，开发针对美国严重疾病的创新小分子治疗药物，市值为 7863 万美元。</p>
<p><strong>运营：</strong> MediciNova, Inc.未报告任何收入部分。</p>
<p><strong>市值：</strong> $78.63M</p>
<p>MediciNova 市值为 7863 万美元，尚未产生收入且处于亏损状态，但在过去五年中已减少亏损。公司最近完成了其第二阶段 OXTOX 研究和第二阶段/第三阶段 COMBAT-ALS 试验的患者招募，均使用 MN-166（ibudilast），该药物已获得 FDA 和 EMA 的孤儿药资格。尽管股价波动性高，MediciNova 经验丰富的管理团队为其在神经退行性疾病领域的管线推进提供了稳定性。最近进行的 5000 万美元后续股权发行旨在增强其在持续临床开发中的财务资源。</p>
<ul>
<li>通过我们的全面资产负债表健康报告，深入了解 MediciNova 的复杂性。</li>
<li>通过我们的详细增长报告评估 MediciNova 的未来收益预期。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/7e64759a-aaa7-429b-bb54-bf40a8c048cc/chart/financial-position-analysis?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/7e64759a-aaa7-429b-bb54-bf40a8c048cc/chart/financial-position-analysis"/></p>
<p>MNOV 财务状况分析截至 2026 年 1 月</p>
<h2>利用机会</h2>
<ul>
<li>在这里开始您的投资之旅，了解我们精选的 334 只美国便士股票。</li>
<li>想探索一些替代方案吗？寻找那些现金流潜力良好但交易价格低于其公允价值的公司。</li>
</ul>
<p><em>这篇文章来自 Simply Wall St，内容具有一般性。<strong>我们提供基于历史数据和分析师预测的评论，采用无偏见的方法，我们的文章并不构成财务建议。</strong> 这并不构成买入或卖出任何股票的推荐，也未考虑您的目标或财务状况。我们的目标是为您提供以基本数据驱动的长期分析。请注意，我们的分析可能未考虑最新的价格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中均没有持仓。</em></p>

Aldeyra治疗

美第奇新星生物技术

AACG

<p>ATA Creativity Global 被认为是在美国股市面临挑战的情况下，三只有前景的低价股之一。该公司的市值为 3684 万美元，提供教育服务，并且财务状况有所改善，净亏损显著减少。尽管存在流动性担忧，但它通过股权融资筹集了 885 万美元。该股票仍然波动，但周波动性有所下降。其他值得注意的低价股包括 Aldeyra Therapeutics 和 MediciNova，均属于生物技术领域，专注于满足医疗需求的治疗方案，尽管尚未盈利，但显示出增长潜力</p>

<p>As the U.S. stock market faces a challenging period with major indexes posting weekly losses and Treasury yields reaching a four-month high, investors are keenly observing potential opportunities in various sectors. Penny stocks, often associated with smaller or newer companies, remain an intriguing area for those seeking growth prospects outside of the mainstream market giants. Despite being considered somewhat niche today, penny stocks can still offer significant potential when backed by robust financial health and strategic positioning within their industries.</p>
<div class="lb-trans"><p>随着美国股市面临挑战，主要指数出现周度亏损，国债收益率达到四个月来的最高点，投资者正在密切关注各个行业的潜在机会。便士股票通常与较小或较新的公司相关，对于那些寻求主流市场巨头之外的增长前景的投资者来说，仍然是一个引人注目的领域。尽管今天被认为有些小众，但便士股票在财务健康和行业内战略定位良好的情况下，仍然可以提供显著的潜力。</p>
</div><h3>Top 10 Penny Stocks In The United States</h3>
<div class="lb-trans"><h3>美国十大便士股票</h3>
</div><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Name</strong></td>
<td><strong>Share Price</strong></td>
<td><strong>Market Cap</strong></td>
<td><strong>Rewards &amp; Risks</strong></td>
</tr>
<tr>
<td>Dingdong (Cayman) (DDL)</td>
<td>$2.61</td>
<td>$559.34M</td>
<td>✅ 4 ⚠️ 1 View Analysis &gt;</td>
</tr>
<tr>
<td>Waterdrop (WDH)</td>
<td>$1.79</td>
<td>$647.38M</td>
<td>✅ 4 ⚠️ 0 View Analysis &gt;</td>
</tr>
<tr>
<td>WM Technology (MAPS)</td>
<td>$0.825</td>
<td>$141.09M</td>
<td>✅ 4 ⚠️ 1 View Analysis &gt;</td>
</tr>
<tr>
<td>LexinFintech Holdings (LX)</td>
<td>$3.00</td>
<td>$504.79M</td>
<td>✅ 4 ⚠️ 2 View Analysis &gt;</td>
</tr>
<tr>
<td>Tuya (TUYA)</td>
<td>$2.25</td>
<td>$1.36B</td>
<td>✅ 4 ⚠️ 1 View Analysis &gt;</td>
</tr>
<tr>
<td>CI&amp;T (CINT)</td>
<td>$4.73</td>
<td>$614.03M</td>
<td>✅ 5 ⚠️ 0 View Analysis &gt;</td>
</tr>
<tr>
<td>Golden Growers Cooperative (GGRO.U)</td>
<td>$5.00</td>
<td>$77.45M</td>
<td>✅ 1 ⚠️ 5 View Analysis &gt;</td>
</tr>
<tr>
<td>Cricut (CRCT)</td>
<td>$4.31</td>
<td>$912.62M</td>
<td>✅ 2 ⚠️ 2 View Analysis &gt;</td>
</tr>
<tr>
<td>BAB (BABB)</td>
<td>$0.91</td>
<td>$6.61M</td>
<td>✅ 2 ⚠️ 3 View Analysis &gt;</td>
</tr>
<tr>
<td>Lifetime Brands (LCUT)</td>
<td>$3.90</td>
<td>$88.36M</td>
<td>✅ 3 ⚠️ 2 View Analysis &gt;</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>名称</strong></td>
<td><strong>股价</strong></td>
<td><strong>市值</strong></td>
<td><strong>收益与风险</strong></td>
</tr>
<tr>
<td>Dingdong (Cayman) (DDL)</td>
<td>$2.61</td>
<td>$559.34M</td>
<td>✅ 4 ⚠️ 1 查看分析 </td>
</tr>
<tr>
<td>Waterdrop (WDH)</td>
<td>$1.79</td>
<td>$647.38M</td>
<td>✅ 4 ⚠️ 0 查看分析 </td>
</tr>
<tr>
<td>WM Technology (MAPS)</td>
<td>$0.825</td>
<td>$141.09M</td>
<td>✅ 4 ⚠️ 1 查看分析 </td>
</tr>
<tr>
<td>LexinFintech Holdings (LX)</td>
<td>$3.00</td>
<td>$504.79M</td>
<td>✅ 4 ⚠️ 2 查看分析 </td>
</tr>
<tr>
<td>Tuya (TUYA)</td>
<td>$2.25</td>
<td>$1.36B</td>
<td>✅ 4 ⚠️ 1 查看分析 </td>
</tr>
<tr>
<td>CI&amp;T (CINT)</td>
<td>$4.73</td>
<td>$614.03M</td>
<td>✅ 5 ⚠️ 0 查看分析 </td>
</tr>
<tr>
<td>Golden Growers Cooperative (GGRO.U)</td>
<td>$5.00</td>
<td>$77.45M</td>
<td>✅ 1 ⚠️ 5 查看分析 </td>
</tr>
<tr>
<td>Cricut (CRCT)</td>
<td>$4.31</td>
<td>$912.62M</td>
<td>✅ 2 ⚠️ 2 查看分析 </td>
</tr>
<tr>
<td>BAB (BABB)</td>
<td>$0.91</td>
<td>$6.61M</td>
<td>✅ 2 ⚠️ 3 查看分析 </td>
</tr>
<tr>
<td>Lifetime Brands (LCUT)</td>
<td>$3.90</td>
<td>$88.36M</td>
<td>✅ 3 ⚠️ 2 查看分析 </td>
</tr>
</tbody>
</table>
</div><p>Click here to see the full list of 334 stocks from our US Penny Stocks screener.</p>
<div class="lb-trans"><p>点击这里查看我们美国便士股票筛选器的 334 只股票完整列表。</p>
</div><p>Let's review some notable picks from our screened stocks.</p>
<div class="lb-trans"><p>让我们回顾一些我们筛选出的显著股票。</p>
</div><h2>ATA Creativity Global (AACG)</h2>
<div class="lb-trans"><h2>ATA Creativity Global (AACG)</h2>
</div><p><strong>Simply Wall St Financial Health Rating:</strong> ★★★★☆☆</p>
<div class="lb-trans"><p><strong>Simply Wall St 财务健康评级：</strong> ★★★★☆☆</p>
</div><p><strong>Overview:</strong> ATA Creativity Global, along with its subsidiaries, offers educational services both in China and internationally, with a market cap of $36.84 million.</p>
<div class="lb-trans"><p><strong>概述：</strong> ATA Creativity Global 及其子公司在中国和国际上提供教育服务，市值为 3684 万美元。</p>
</div><p><strong>Operations:</strong> The company's revenue segments include CN¥256.91 million from Segment Adjustment and CN¥22.99 million from Other Educational Services.</p>
<div class="lb-trans"><p><strong>运营：</strong> 公司的收入部分包括来自细分调整的人民币 2.5691 亿元和其他教育服务的人民币 2299 万元。</p>
</div><p><strong>Market Cap:</strong> $36.84M</p>
<div class="lb-trans"><p><strong>市值：</strong> $36.84M</p>
</div><p>ATA Creativity Global, with a market cap of $36.84 million, has shown improvement in its financials despite being unprofitable. The company reduced its net loss significantly over the past year and reported a net income of CN¥2.37 million for Q3 2025, compared to a net loss previously. Its short-term assets exceed long-term liabilities but fall short against short-term liabilities, highlighting potential liquidity concerns. Recent efforts to raise $8.85 million through equity offerings suggest ongoing capital needs. While the management and board are seasoned, the stock remains highly volatile with decreased weekly volatility from 18% to 12%.</p>
<div class="lb-trans"><p>ATA Creativity Global 市值为 3684 万美元，尽管尚未盈利，但其财务状况有所改善。公司在过去一年中显著减少了净亏损，并在 2025 年第三季度报告了人民币 237 万元的净收入，而之前则是净亏损。其短期资产超过长期负债，但不足以覆盖短期负债，突显出潜在的流动性问题。最近通过股权发行筹集 885 万美元的努力表明其持续的资本需求。尽管管理层和董事会经验丰富，但该股票仍然高度波动，周度波动率从 18% 降至 12%。</p>
</div><ul>
<li>Click here and access our complete financial health analysis report to understand the dynamics of ATA Creativity Global.</li>
<li>Understand ATA Creativity Global's track record by examining our performance history report.</li>
</ul>
<div class="lb-trans"><ul>
<li>点击这里访问我们的完整财务健康分析报告，以了解 ATA Creativity Global 的动态。</li>
<li>通过查看我们的业绩历史报告，了解 ATA Creativity Global 的表现记录。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/72e41983-3668-429b-8c7c-04ae55a7571c/chart/debt-equity-history-analysis" alt="" original-src="https://images.simplywall.st/company/72e41983-3668-429b-8c7c-04ae55a7571c/chart/debt-equity-history-analysis"/></p>
<p>AACG Debt to Equity History and Analysis as at Jan 2026</p>
<div class="lb-trans"><p>AACG 债务与股本历史及分析截至 2026 年 1 月</p>
</div><h2>Aldeyra Therapeutics (ALDX)</h2>
<div class="lb-trans"><h2>Aldeyra Therapeutics (ALDX)</h2>
</div><p><strong>Simply Wall St Financial Health Rating:</strong> ★★★★★☆</p>
<div class="lb-trans"><p><strong>Simply Wall St 财务健康评级：</strong> ★★★★★☆</p>
</div><p><strong>Overview:</strong> Aldeyra Therapeutics, Inc. is a biotechnology company focused on discovering and developing therapies for immune-mediated and metabolic diseases, with a market cap of approximately $278.55 million.</p>
<div class="lb-trans"><p><strong>概述：</strong> Aldeyra Therapeutics, Inc.是一家生物技术公司，专注于发现和开发针对免疫介导和代谢疾病的疗法，市值约为 2.7855 亿美元。</p>
</div><p><strong>Operations:</strong> Aldeyra Therapeutics, Inc. has not reported any revenue segments.</p>
<div class="lb-trans"><p><strong>运营：</strong> Aldeyra Therapeutics, Inc.尚未报告任何收入部分。</p>
</div><p><strong>Market Cap:</strong> $278.55M</p>
<div class="lb-trans"><p><strong>市值：</strong> $278.55M</p>
</div><p>Aldeyra Therapeutics, with a market cap of US$278.55 million, is pre-revenue and remains unprofitable, yet it has managed to reduce its losses over the past five years. The company recently faced an FDA extension for its reproxalap NDA due to additional data requests but received no major deficiencies from the agency. Aldeyra's cash position exceeds its total debt, providing a sufficient runway for operations beyond a year. Despite high share price volatility and negative return on equity, Aldeyra's seasoned management and board offer stability as it pursues advancements in immune-mediated therapies.</p>
<div class="lb-trans"><p>Aldeyra Therapeutics 市值为 2.7855 亿美元，尚未产生收入且仍处于亏损状态，但在过去五年中已成功减少亏损。公司最近因额外数据请求而面临 FDA 对其 reproxalap NDA 的延期，但未收到该机构的重大缺陷。Aldeyra 的现金状况超过其总债务，为其运营提供了一年以上的充足资金。尽管股价波动性高且股本回报率为负，Aldeyra 经验丰富的管理层和董事会为其在免疫介导疗法的进展提供了稳定性。</p>
</div><ul>
<li>Get an in-depth perspective on Aldeyra Therapeutics' performance by reading our balance sheet health report here.</li>
<li>Learn about Aldeyra Therapeutics' future growth trajectory here.</li>
</ul>
<div class="lb-trans"><ul>
<li>通过阅读我们的资产负债表健康报告，深入了解 Aldeyra Therapeutics 的表现。</li>
<li>在这里了解 Aldeyra Therapeutics 的未来增长轨迹。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/55e4738e-9ff5-4d4f-8334-fd9b51fc6541/chart/debt-equity-history-analysis" alt="" original-src="https://images.simplywall.st/company/55e4738e-9ff5-4d4f-8334-fd9b51fc6541/chart/debt-equity-history-analysis"/></p>
<p>ALDX Debt to Equity History and Analysis as at Jan 2026</p>
<div class="lb-trans"><p>ALDX 债务与股本历史及分析截至 2026 年 1 月</p>
</div><h2>MediciNova (MNOV)</h2>
<div class="lb-trans"><h2>MediciNova (MNOV)</h2>
</div><p><strong>Simply Wall St Financial Health Rating:</strong> ★★★★★★</p>
<div class="lb-trans"><p><strong>Simply Wall St 财务健康评级：</strong> ★★★★★★</p>
</div><p><strong>Overview:</strong> MediciNova, Inc. is a biopharmaceutical company that develops novel small molecule therapeutics for serious diseases with unmet medical needs in the United States, with a market cap of $78.63 million.</p>
<div class="lb-trans"><p><strong>概述：</strong> MediciNova, Inc.是一家生物制药公司，开发针对美国严重疾病的创新小分子治疗药物，市值为 7863 万美元。</p>
</div><p><strong>Operations:</strong> MediciNova, Inc. does not report any revenue segments.</p>
<div class="lb-trans"><p><strong>运营：</strong> MediciNova, Inc.未报告任何收入部分。</p>
</div><p><strong>Market Cap:</strong> $78.63M</p>
<div class="lb-trans"><p><strong>市值：</strong> $78.63M</p>
</div><p>MediciNova, with a market cap of US$78.63 million, is pre-revenue and unprofitable but has reduced losses over the past five years. The company recently completed patient enrollment for its Phase 2 OXTOX study and Phase 2b/3 COMBAT-ALS trial, both utilizing MN-166 (ibudilast), which has Orphan Drug Designation from the FDA and EMA. Despite high share price volatility, MediciNova's seasoned management team provides stability as it advances its pipeline in neurodegenerative diseases. A recent follow-on equity offering of US$50 million aims to bolster financial resources amid ongoing clinical developments.</p>
<div class="lb-trans"><p>MediciNova 市值为 7863 万美元，尚未产生收入且处于亏损状态，但在过去五年中已减少亏损。公司最近完成了其第二阶段 OXTOX 研究和第二阶段/第三阶段 COMBAT-ALS 试验的患者招募，均使用 MN-166（ibudilast），该药物已获得 FDA 和 EMA 的孤儿药资格。尽管股价波动性高，MediciNova 经验丰富的管理团队为其在神经退行性疾病领域的管线推进提供了稳定性。最近进行的 5000 万美元后续股权发行旨在增强其在持续临床开发中的财务资源。</p>
</div><ul>
<li>Navigate through the intricacies of MediciNova with our comprehensive balance sheet health report here.</li>
<li>Assess MediciNova's future earnings estimates with our detailed growth reports.</li>
</ul>
<div class="lb-trans"><ul>
<li>通过我们的全面资产负债表健康报告，深入了解 MediciNova 的复杂性。</li>
<li>通过我们的详细增长报告评估 MediciNova 的未来收益预期。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/7e64759a-aaa7-429b-bb54-bf40a8c048cc/chart/financial-position-analysis" alt="" original-src="https://images.simplywall.st/company/7e64759a-aaa7-429b-bb54-bf40a8c048cc/chart/financial-position-analysis"/></p>
<p>MNOV Financial Position Analysis as at Jan 2026</p>
<div class="lb-trans"><p>MNOV 财务状况分析截至 2026 年 1 月</p>
</div><h2>Taking Advantage</h2>
<div class="lb-trans"><h2>利用机会</h2>
</div><ul>
<li>Embark on your investment journey to our 334 US Penny Stocks selection here.</li>
<li>Want To Explore Some Alternatives? Find companies with promising cash flow potential yet trading below their fair value.</li>
</ul>
<div class="lb-trans"><ul>
<li>在这里开始您的投资之旅，了解我们精选的 334 只美国便士股票。</li>
<li>想探索一些替代方案吗？寻找那些现金流潜力良好但交易价格低于其公允价值的公司。</li>
</ul>
</div><p><em>This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.</em></p>
<div class="lb-trans"><p><em>这篇文章来自 Simply Wall St，内容具有一般性。<strong>我们提供基于历史数据和分析师预测的评论，采用无偏见的方法，我们的文章并不构成财务建议。</strong> 这并不构成买入或卖出任何股票的推荐，也未考虑您的目标或财务状况。我们的目标是为您提供以基本数据驱动的长期分析。请注意，我们的分析可能未考虑最新的价格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中均没有持仓。</em></p>
</div>

ATA Creativity Global 位列三只有潜力的便士股之中